🇺🇸 FDA
Pipeline program

Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

APHP180591

Phase 3 small_molecule active

Quick answer

Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota for Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials